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A detailed analysis of practice patterns associated with
individual variceal bleeding episodes has not been per-
formed. 
OBJECTIVES: To characterize the treatment sequence,
associated costs of bleeding episodes and how sequencing
affects the cost of therapy. 
METHODS: A retrospective evaluation of electronic da-
tabases and medical charts for patients who underwent
esophagogastroduodenoscopy at the Portland VA be-
tween January 1993 and May 1997 was performed. An
episode of care was defined as an index bleed with fol-
low-up to death or 6 months. 
RESULTS: All 100 bleeding episodes occurring in 79 pa-
tients were initially managed in the emergency room. Di-
agnostic endoscopy was performed in 38% of episodes,
banding endoscopy in 28%, sclerotherapy endoscopy in
32%, and banding plus sclerotherapy in 2%. Non-phar-
macologic therapies (including sclerotherapy, banding,
TIPS, balloon tamponade, and surgical shunt) were used
exclusively in 52 bleeding episodes. Octreotide was used
in 41 episodes and vasopressin was utilized in 7 episodes.
Pharmacologic therapy was administered prior to endo-
scopy in 46% and 29% of episodes for octreotide and va-
sopressin, respectively. Ttreatment groups receiving phar-
macologic therapies were more expensive ($19,193 
$1900 for octreotide and $24,957  $9537 for vaso-
pressin) than the non-pharmacologic therapy group
($13,647  $1471), reflecting patients with more severe
bleeds. Episodes of care where octreotide was given prior
to endoscopy were shown to have lower overall inpatient
costs ($15,653  $8346) than episodes of care where oc-
treotide was given after endoscopy ($22,265  $14,180). 
CONCLUSION: Understanding the costs of various
practice patterns for variceal bleeding can help manage
the potentially significant economic burden associated
with this disease.
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RATE OF GI DISTRESS AMONG PATIENTS 
TREATED WITH CELECOXIB, PLACEBO,
OR NSAIDs USING THREE DIFFERENT 
STATISTICAL METHODS
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Adverse event (AE) rates are generally reported as crude
rates, consisting of patients reporting an AE (numerator)
among those randomized and treated (denominator).
Crude rates, however, may be problematic if exposure
differs among study drug, comparator, or placebo. Cele-
coxib, a novel cyclooxygenase (COX)-2 inhibitor, has
demonstrated reduced AE rates compared to NSAIDs
(comparator), while having similar AE rates as placebo. 
OBJECTIVES: Compare the rate of GI distress using
both crude and observed person-time rates, while using
survival analysis to verify the above rates. 
METHODS: The analysis was based on eight phase-III
celecoxib clinical trials. GI distress patients were defined
as having one of the following moderate-to-severe events:
abdominal pain, nausea, or dyspepsia. AE rates were cal-
culated using both crude rates and patient 12-week ob-
servation. Cumulative AE probabilities were calculated
using survival analysis. 
RESULTS: GI distress rates based on patient 12-week
follow-up were: NSAIDs (17.5%), celecoxib (10.4%),
and placebo (12.1%). Celecoxib and placebo arms had
similar Kaplan-Meier curves, which differed significantly
from the NSAID-arm. Three-month cumulative probabil-
ities from survival analysis were: NSAIDs (12.9%), cele-
coxib (8.1%), and placebo (8.5%). However, crude rates
were: NSAIDs (13.5%), celecoxib (8.1%), and placebo
(6.9%). For each statistical method, NSAIDs significantly
differed from celecoxib or placebo (p  0.01), while cele-
coxib and placebo were similar (p  NS). Differences in
GI distress rates between the crude rate and patient-time
observation were: placebo (5.2%), NSAIDs (4.0%), and
celecoxib (2.3%). 
CONCLUSIONS: Differences between crude rates and
person-time results were less apparent for celecoxib and
NSAIDs than placebo due to fewer early withdrawals in
these arms relative to placebo. Survival analysis con-
firmed patient-12-week observation was more appropri-
ate than the crude rate method.
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A METHOD FOR COMPARING DISPARATE 
OUTCOME MEASURES IN OVERACTIVE 
BLADDER CLINICAL TRIALS
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Researchers have reported varying endpoints in assessing
treatment options for overactive bladder (OAB). No pub-
lished trials have compared controlled release once-daily
oxybutynin-XL (OXY-XL) and twice daily tolterodine
(TOL) using equivalent clinical endpoint for success,
making it difficult to compare therapies. 
OBJECTIVE: Describe approach for comparing dispar-
ate OAB treatment outcome measures. 
METHODS: Clinical trial data supplemented with litera-
ture identified randomized controlled and open label
safety trials involving OXY-XL or TOL. Patient out-
